Followers | 833 |
Posts | 119837 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Tuesday, May 14, 2024 4:25:51 PM
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html
3/31/24 cash = $542M, down from $578M at 12/31/23.
Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent AVIR News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 08:04:05 PM
- Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 08:15:03 PM
- Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:43:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:08 PM
- Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:18:59 PM
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:29:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:25:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:24:58 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:01 PM
- Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 • GlobeNewswire Inc. • 11/13/2023 12:00:00 PM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM